Indegene Limited — Investor Meet, 06-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Indegene Limited recorded revenues of ₹7,204 million for Q3 FY25, marking a sequential growth of 4.9% and a year-on-year increase of 7%. EBITDA reached ₹1,501 million, reflecting an 18.5% sequential rise, with EBITDA margins improving to 20.8%. The profit after tax (PAT) stood at ₹1,097 million, up 19.6% sequentially, leading to a PAT margin of 15.2%. Revenue from the top five accounts grew 3.1% sequentially, and the number of active clients rose from 68 to 75.

2. **Future Outlook and Growth Drivers:** Management highlighted a cautious recovery in the biopharma industry for FY25, anticipating higher demand for digital-first commercial services driven by the need for cost efficiency as drug pricing pressures persist. Renewals of major client engagements were predominantly successful, with prospects for expansion into new regions and upscaling existing client relationships.

3. **Order Book and Operational Updates:** Upcoming quarters are expected to benefit from the five new key deals won, each valued between ₹20 million to ₹40 million, aimed at existing and new customers. Management indicated strong renewal rates as a positive indicator for future revenue.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts inquired about revenue projections; management noted growth is expected to stem from mid-tier pharma clients beyond the top 20.

- **Market Position and Competitive Landscape:** Queries regarding competitive dynamics revealed confidence in leveraging partnerships with Veeva and Salesforce amidst industry shifts.

- **Operational Challenges or Risks:** Management acknowledged challenges in integration post-acquisition but emphasized a firm governance framework for evaluating future acquisitions.

- **Capex and Capital Allocation:** Management discussed disciplined capital allocation strategies, particularly in pursuit of M&A opportunities.

- **Strategic Priorities and Long-Term Vision:** Insights shared on long-term growth initiatives included strengthening technology capabilities to improve efficiency and effectiveness.

5. **Market or Regulatory Updates:** Management noted that external pressures from drug pricing and increasing regulatory complexities are influencing market dynamics, emphasizing the need for enhanced operational efficiencies.

6. **Strategic Focus Areas:** A notable emphasis on expanding capabilities in omnichannel marketing and technology integration was observed, reflecting a clear focus on improving service delivery while adapting to evolving client needs.

7. **Investor Insight:** The displayed financial health coupled with strong growth potential, particularly in the expanding mid-tier pharmaceutical segment, aligns with a ‘buy’ position considering the promising strategic outlook despite potential operational challenges.